Corporate Presentation S E E K I N G G E N E T H E R A P Y C U R E S August 2021 1 NASDAQ: RCKT Important Information 2 Cautionary Statement Regarding Forward-Looking Statements Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesio ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Mayur Kasetty - Director of Business Development and Operations Gaurav Shah - CEO Claudine Prowse - SVP, Strategy & Corporate Development Gayatri Rao - Chief Development Officer of LVV, SVP Jonathan Schwartz - Chief Medical Officer & Clinical Development and SVP Conference Call Participants Dae Gon Ha - Stifel Gil Blum - Needham and Company Yaron Werber - Cowen & Co. Mani Foroohar - SVB ...

For the transition period from to Commission file number: 001-36829 Rocket Pharmaceuticals, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36829 Rocket Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36829 Rocket Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3475813 (State or Other Jurisdic ...

Corporate Presentation 1 January 2021 S E E K I N G G E N E T H E R A P Y C U R E S NASDAQ: RCKT Cautionary Statement Regarding Forward-Looking Statements 2 Important Information Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesi ...

pharma 1 ASH: Breakout Session December 8, 2019 Q&A Panelists Brian Beard, Ph.D.: AVP, Chemistry Manufacturing and Control, LVV & AAV, Rocket Pharmaceuticals Agnieszka Czechowicz M.D., Ph.D.: Assistant Professor of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine at the Stanford University School of Medicine (FA) Donald (Don) Kohn, M.D.: Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics Molecular and Medical Pharmacology Professor at UCLA and Principal Inves ...

·p·h a r m a August 2019 Important Information Cautionary Statement Regarding Forward-Looking Statements Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, including in collaboration with academic partners, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantil ...